A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
@article{Kipnes2010AOS, title={A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes}, author={M. Kipnes and P. Hollander and K. Fujioka and I. Gantz and T. Seck and N. Erondu and Y. Shentu and K. Lu and S. Suryawanshi and M. Chou and A. Johnson-Levonas and S. Heymsfield and D. Shapiro and K. Kaufman and J. Amatruda}, journal={Diabetes}, year={2010}, volume={12} }
Aim: To evaluate the efficacy and safety of taranabant in overweight and obese patients with type 2 diabetes mellitus (T2DM).
Topics from this paper
Paper Mentions
Interventional Clinical Trial
A worldwide study with extension in patients with type 2 diabetes mellitus to assess the
safety and tolerability as well as the effects of treatment with an investigational drug for… Expand
Conditions | Obesity Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus |
---|---|
Intervention | Drug |
43 Citations
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
- Medicine
- International Journal of Obesity
- 2010
- 70
- PDF
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
- Medicine
- Diabetes, obesity & metabolism
- 2017
- 40
The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice
- Medicine
- Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
- 2013
- 27
A Randomized Trial of Lifestyle Modification and Taranabant for Maintaining Weight Loss Achieved With a Low‐Calorie Diet
- Medicine
- Obesity
- 2010
- 27
Possible Role of Adipose Tissue and Endocannabinoid System in COVID‐19 Pathogenesis: Can Rimonabant Return?
- Medicine
- Obesity
- 2020
- 4
New approaches to the pharmacological treatment of obesity: Can they break through the efficacy barrier?
- Medicine
- Pharmacology Biochemistry and Behavior
- 2010
- 68
Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs
- Medicine
- Biomolecules
- 2020
- 4
- Highly Influenced
- PDF
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
- Medicine
- Journal of obesity
- 2011
- 202
- PDF
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons
- Medicine
- Nature Reviews Drug Discovery
- 2012
- 134
- PDF
References
SHOWING 1-10 OF 72 REFERENCES
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin
- Medicine
- Diabetic medicine : a journal of the British Diabetic Association
- 2005
- 90
Is rimonabant a safe and effective therapy for sustained weight loss and improved cardiometabolic risk factors?
- Medicine
- Nature Clinical Practice Cardiovascular Medicine
- 2006
- 6
A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
- Medicine
- International Journal of Obesity
- 2010
- 60
- PDF
A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
- Medicine
- International Journal of Obesity
- 2010
- 70
- PDF
The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study
- Medicine
- Journal of internal medicine
- 2000
- 183
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
- Medicine
- The Lancet
- 2006
- 703
- PDF
Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.
- Medicine
- European heart journal
- 2008
- 136
- PDF
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
- Medicine
- The New England journal of medicine
- 2005
- 1,324
- PDF
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
- Medicine
- Diabetes care
- 2002
- 250
- PDF